Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index; 13 of the 23 sources its claims cite were checked for support.

Guided self-help for anxiety among Huntington’s disease gene expansion carriers (GUIDE-HD) compared to treatment as usual: a randomised controlled feasibility trial

Open access
Dale, Maria, Eccles, Fiona J. R., Melvin, Katie, Khan, Zaynah, Jones, Lee, Zarotti, Nicolò, Kiani, Reza, Johnson, Jenny, Wells, Robert, Simpson, Jane · 2023 · Pilot and Feasibility Studies

Published version of a preprint

Abstract

Background: Huntington’s disease (HD) is an adult-onset genetic neurodegenerative condition associated with cognitive decline, motor impairments, and emotional difficulties. Anxiety affects up to 71% of HD gene expansion carriers (i.e., those with the version of the gene that causes HD) and can negatively impact quality of life, worsen other HD symptoms, and increase suicide risk. Therefore, helping people with their anxiety should be a clinical priority. A significant evidence base now exists for low-cost talking therapies for anxiety, such as guided self-help, and with people with other neurodegenerative conditions (e.g., Parkinson’s disease). However, this type of intervention has not been specifically assessed with HD gene expansion carriers. Methods: This protocol describes an exploratory randomised controlled feasibility study of a psychological intervention for anxiety for HD gene expansion carriers. The 10 session guided self-help intervention ('GUIDE-HD') is based on a blend of second and third wave cognitive behavioural models of anxiety (cognitive behaviour therapy [CBT] and acceptance and commitment therapy [ACT]) and is adapted to meet the specific needs of an HD population. This study will compare guided self-help with treatment as usual (TAU), with 15 HD gene expansion carriers randomly allocated to each group. Participants will be recruited across the UK. Quantitative data will be collected pre-intervention, immediately post-intervention, 3-month post-intervention and 6-month post-intervention. Qualitative data will be collected at one month post-intervention from participants, including HD carers. The data will be analysed to assess whether the current intervention and study design are feasible to progress to a larger randomised controlled trial. Feasibility has been defined in terms of recruitment rate, retention rate to both trial arms, intervention adherence, and acceptability of the intervention and measurement tools. Discussion: Given the lack of evidenced interventions to date to support the wellbeing of people with the expanded Huntington’s gene, this study will assess the feasibility of progressing this particular intervention to a full trial. To try and increase the acceptability of the intervention, a number of stakeholders, including those affected by HD and in caring roles, have been fundamental to the creation of the intervention (e.g., therapy manual, planned therapy process) to date. Trial registration: Trial ID: ISRCTN47330596 . Date registered: 28/09/2022. Protocol version and date: Version 2, 09/06/22. Trial sponsor organisation and contact: Leicestershire Partnership NHS Trust (Dave Clarke). Role of sponsor: Overall responsibility for the conduct and governance of the trial. Role of funder: Review of initial research proposal. © 2023, BioMed Central Ltd., part of Springer Nature.

Overview

CoChat Summary

## TL;DR

This paper is a protocol for GUIDE-HD, a 2-arm randomised controlled feasibility trial testing whether a 10-session guided self-help intervention for anxiety can be delivered and accepted in Huntington’s disease gene expansion carriers, compared with treatment as usual. The trial is designed to inform whether a full efficacy RCT is feasible, using recruitment, retention, adherence, and acceptability as the main go/no-go criteria.

## Key findings

  • Not stated in the paper.
  • The background states anxiety affects up to 71% of HD gene expansion carriers and can negatively affect quality of life, worsen other HD symptoms, and increase suicide risk.
  • The protocol sets a target sample of 30 HD participants (15 per arm), with a total sample aimed at 36 including carers.
  • Progression criteria are explicitly defined: ≥60% of eligible participants consenting, ≥70% retention at 3- and 6-month follow-up, ≥90% completion of at least one primary outcome measure including 6-month follow-up, >75% of intervention activities completed, and >75% of completers rating the intervention acceptable.

## Methods

  • Design: 2-arm randomised controlled feasibility trial with 1:1 allocation to guided self-help plus treatment as usual versus treatment as usual alone; quantitative and qualitative data are collected.
  • Sample/data: HD gene expansion carriers in the UK with confirmed HTT CAG ≥ 36, clinical anxiety, and premanifest or early-stage manifest HD; carers may also participate in qualitative work and some intervention support.
  • Analysis: Feasibility outcomes are analysed with descriptive statistics; qualitative interviews are analysed using framework analysis; stratified/block randomisation is used to balance premanifest vs manifest participants.

## Limitations

  • The paper states this is a feasibility study, so no formal power calculation was done and the sample is small.
  • As stated in the paper, the intervention team cannot be blinded for post-intervention acceptability ratings and repeated outcome measures; blind assessment will not be possible.
  • Evident from the protocol text: the paper reports planned methods only, so it provides no results on feasibility, acceptability, or clinical outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s40814-023-01364-5

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 GUIDE-HD study flow diagram using the CONSORT framework (2010)
Fig. 1 GUIDE-HD study flow diagram using the CONSORT framework (2010)CC BY · PubMed Central
Fig. 2 GUIDE-HD schedule of enrolment, interventions, and assessments for participants with the expanded HD gene using the SPIRIT 2013 Statement
Fig. 2 GUIDE-HD schedule of enrolment, interventions, and assessments for participants with the expanded HD gene using the SPIRIT 2013 StatementCC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 5 Not checked · 31 Own results and interpretations

5 more claims

Create a free account to see all 47 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 9
  • Probably not a substantial claim. 33

Create a free account to see these claims.

Citations

Cites

Show all 45 references

Cited by

See all 4

Metadata

Authors
Dale, M., Eccles, F. J. R., Melvin, K., Khan, Z., Jones, L., Zarotti, N., Kiani, R., Johnson, J., Wells, R., & Simpson, J.
Affiliations
  • Leicestershire Partnership NHS Trust (GB)
  • Lancaster University (GB)
  • Salford Royal Hospital (GB)
Corresponding author
Simpson, Jane
Venue
Pilot and Feasibility Studies
Published
2023-09-12
Volume
9
Issue
1
Pages
159-159
ISSN
2055-5784 (ISSN-L)
OpenAlex
W4386688402
Cited by
4
References
45
Citations by year
2025: 3 · 2024: 1
FWCI
1.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Pilot and Feasibility Studies (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lancaster EPrints (Lancaster University) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Jacques und Gloria Gossweiler-Stiftung
Topics
  • Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
Huntington's disease, gene expansion carriers, anxiety, guided self-help, cognitive behavioral therapy, acceptance and commitment therapy, feasibility, psychological intervention, neurodegenerative diseases, caregivers, treatment acceptability, trial recruitment and retention, suicide risk, quality of life, treatment as usual comparison

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guided self-help for anxiety among Huntington’s disease gene expansion carriers (GUIDE-HD) compared to treatment as usual: a randomised controlled feasibility trial. https://app.cochat.ai/papers/10.1186/s40814-023-01364-5
The paper
Dale, M., Eccles, F. J. R., Melvin, K., Khan, Z., Jones, L., Zarotti, N., Kiani, R., Johnson, J., Wells, R., & Simpson, J. (2023). Guided self-help for anxiety among Huntington’s disease gene expansion carriers (GUIDE-HD) compared to treatment as usual: a randomised controlled feasibility trial. Pilot and Feasibility Studies. https://doi.org/10.1186/s40814-023-01364-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.